A Phase II Safety Study of Systemic Nanoparticle Paclitaxel (ABI-007)for In-Stent Restenosis.

Trial Profile

A Phase II Safety Study of Systemic Nanoparticle Paclitaxel (ABI-007)for In-Stent Restenosis.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Mar 2013

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Oct 2011 Official title amended as reported by ClinicalTrials.gov.
    • 09 Mar 2010 Actual patient number (76) added as reported by ClinicalTrials.gov.
    • 23 Jun 2009 Additional lead trial investigator (Iglesias J) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top